Receptor–receptor interactions involving adenosine A1 or dopamine D1 receptors and accessory proteins
- 6 October 2006
- journal article
- review article
- Published by Springer Nature in Journal Of Neural Transmission-Parkinsons Disease and Dementia Section
- Vol. 114 (1) , 93-104
- https://doi.org/10.1007/s00702-006-0566-7
Abstract
The molecular basis for the known intramembrane receptor–receptor interactions among heptahelical receptors (G protein coupled receptors, GPCR) was postulated to be heteromerization based on receptor subtype specific interactions between different types of homomers of GPCR. Adenosine and dopamine receptors in the basal ganglia have been fundamental to demonstrate the existence of receptor heteromers and the functional consequences of such molecular interactions. The heterodimer is only one type of heteromeric complex and the evidence is equally compatible with the existence of higher order heteromeric complexes, where also adapter proteins such as homer proteins and scaffolding proteins can exist, assisting in the process of linking the GPCR and ion channel receptors together in a receptor mosaic that may have special integrative value and may constitute the molecular basis for learning and memory. Heteromerization of D2 dopamine and A2A adenosine receptors is reviewed by Fuxe in another article in this special issue. Here, heteromerization between D1 dopamine and A1 adenosine receptors is reviewed. Heteromers formed by dopamine D1 and D2 receptors and by adenosine A1 and A2A receptors also occur in striatal cells and open new perspectives to understand why two receptors with apparently opposite effects are expressed in the same neuron and in the nerve terminals. The role of accessory proteins also capable of interacting with receptor–receptor heteromers in regulating the traffic and the molecular physiology of these receptors is also discussed. Overall, the knowledge of the reason why such complex networks of receptor–receptor and receptor–protein interactions occur in striatal cells is crucial to develop new strategies to combat neurological and neuropsychiatric diseases.Keywords
This publication has 79 references indexed in Scilit:
- The Two-State Dimer Receptor Model: A General Model for Receptor DimersMolecular Pharmacology, 2006
- Dimer-based model for heptaspanning membrane receptorsTrends in Biochemical Sciences, 2005
- Dual Signaling Regulated by Calcyon, a D1 Dopamine Receptor Interacting ProteinScience, 2000
- Ecto-ADA in the development of theimmune systemImmunology Today, 1998
- Ecto-adenosine deaminase: An ecto-enzyme and a costimulatory protein acting on a variety of cell surface receptorsDrug Development Research, 1998
- Regulation of phosphoinositide turnover in neonatal rat cerebral cortex by group I‐ and II‐ selective metabotropic glutamate receptor agonistsBritish Journal of Pharmacology, 1998
- The Novel Metabotropic Glutamate Receptor Agonist 2R,4R-APDC Potentiates Stimulation of Phosphoinositide Hydrolysis in the Rat Hippocampus by 3,5-dihydroxyphenylglycine: Evidence for a Synergistic Interaction Between Group 1 and Group 2 ReceptorsNeuropharmacology, 1996
- Adenosine deaminase affects ligand‐induced signalling by interacting with cell surface adenosine receptorsFEBS Letters, 1996
- Immunological identification of A1 adenosine receptors in brain cortexJournal of Neuroscience Research, 1995
- Desensitization, phosphorylation and palmitoylation of the human dopamine D1 receptorEuropean Journal of Pharmacology: Molecular Pharmacology, 1994